Suggestions
Lars Ohman
CEO at Immunscape AB
Lars Ohman is a seasoned pharmaceutical industry professional with over 35 years of experience, currently serving as the CEO of Immunscape AB.12 Here's a comprehensive overview of his background and current roles:
Professional Experience
Current Positions::
- CEO at Immunscape AB (since July 2016)1
- Chairman of the Board at Lipigon Pharmaceuticals AB (since May 2022)1
- Co-Founder of Cordator Life Science AB (since January 2018)1
- CEO of Kubator Therapeutics AB (since July 2012)1
- Chairman of the Board at Kubera Pharmaceuticals AB (since July 2012)1
Previous Experience::
- Vice President of Business Development at Karo Bio AB (June 2006 - February 2014)1
- Director of Business Development at Karo Bio (March 2002 - June 2005)1
- Project Manager at Karo Bio (1997 - 2002)1
- Head of Cell Culture and Fermentation Technology at Karo Bio AB (June 1989 - August 2002)1
Expertise
Lars Ohman specializes in:
- Defining partnering strategies
- Identifying potential partners
- Assessing partnering opportunities
- Negotiating partnering deals
- Strategic marketing, particularly in metabolic diseases, oncology, and CNS
- Portfolio management
- Technology and product in- and out-licensing
- Corporate strategy development1
Education
- MBA in Management from Stockholm School of Economics (2002 - 2004)1
- Studied at KTH Royal Institute of Technology (1977 - 1991)1
Notable Achievements
At Immunscape, Lars Ohman has been instrumental in establishing the company as a notable player in immuno-oncology. In 2022, Immunscape secured a significant partnership with Orion, which Ohman described as a big deal for the company.3
Company Focus
Immunscape, under Ohman's leadership, focuses on the discovery and development of immunotherapy drugs for cancer and immune disorders.1 The company aims to innovate in the competitive field of immuno-oncology, working to outmaneuver larger pharmaceutical companies in this space.3
Lars Ohman's extensive experience in the pharmaceutical industry, combined with his roles across multiple biotech companies, positions him as a key figure in the development of novel therapies, particularly in the areas of immunotherapy and metabolic diseases.
